Abstract:BACKGROUNDGlioblastoma multiforme (GBM) is an aggressively malignant brain tumor known for its high recurrence rates and dismal survival outcomes. Despite advancements in surgical and therapeutic strategies, the prognosis for GBM patients remains poor. This study applies proteomic analysis to postoperative GBM tumor specimens to identify molecular markers that could enhance prognosis prediction. Through the analysis of protein expression profiles before and after tumor recurrence, we identified significant alterations in protein pathways via Gene Set Enrichment Analysis (GSEA), highlighting potential biomarkers for disease outcome prediction. METHODSWe employed Sequential Window Acquisition of All Theoretical Fragment Ion Spectra (SWATH-MS) proteomics to analyze protein samples from both primary and recurrent GBM patients. Gene Set Enrichment Analysis (GSEA) was utilized to compare protein expression profiles and discern significantly altered pathways. RESULTSAnalysis revealed 778 differentially expressed proteins (DEPs), with notable alterations in pathways such as glycolysis, interleukin signaling, and MAPK signaling. Proteins such as TOLLIP, ENO1, and ITGA2B emerged as potential prognostic markers. Validation through an online tumor prognostic analysis platform (ToPP), integrated with The Cancer Genome Atlas (TCGA) data, facilitated the development of a prognostic risk score model. This model effectively categorized patients into high and low-risk groups based on their protein expression profiles, enhancing the prediction of patient outcomes. The proteins and pathways identified offer new insights into the molecular dynamics of GBM postoperatively. The association between protein expression profiles and patient prognosis underscores the potential of these markers in developing customized therapeutic strategies. Additionally, the prognostic risk score model serves as a valuable tool for improving prognostic accuracy and could guide personalized treatment plans. CONCLUSIONProteomic profiling of GBM tumors significantly contributes to uncovering the molecular mechanisms driving this aggressive cancer and facilitates the development of dependable prognostic tools. These findings not only affirm the critical role of proteomics in cancer research but also advance personalized medicine strategies in GBM management.

Research on Glioma Protein Profile and Screening of Its Disease-related Proteins in Tissues

Identification of Glioblastoma Phosphotyrosine-Containing Proteins with Two-Dimensional Western Blotting and Tandem Mass Spectrometry

Proteomics Identification of Proteins in Human Cortex Using Multidimensional Separations and MALDI Tandem Mass Spectrometer

Quantitative Proteomic Analysis of Oligodendrogliomas with and Without 1p/19q Deletion

Proteomic Analysis of Cerebrospinal Fluid: Toward the Identification of Biomarkers for Gliomas.

Establishment of Diagnostic Model of Cerebrospinal Protein Fingerprint Pattern for Glioma and Its Clinical Application

Fingerprint pattern analysis of glioma CSF protein with mass spectrometry and its clinical significance

Mass Spectrometric Analysis of Cerebrospinal Fluid Protein for Glioma and Its Clinical Application

Cnsc-08. Prognostic Biomarker Discovery Through Proteomic Analysis Of Glioblastoma Multiforme

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population and brain benign tumo

Serum Protein Fingerprinting Coupled with Artificial Neural Network Distinguishes Glioma from Healthy Population or Brain Benign Tumor

Identification of Discrepant Proteins Between Normal Ependyma and Ependymoma of Spinal Cord by Using Proteomics Technology

Proteomic Distributions in CD34+Microvascular Niche Patterns of Glioblastoma

Analysis of Differentially Expressed Genes Based on Microarray Data of Glioma.

Screening and Identification of Differential Expression Proteins from Pancreatic Carcinoma and Neighboring Normal Pancreatic Tissues

Putting Proteomics Into Immunotherapy for Glioblastoma

Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics

Proteomic Profiling of Gliomas Unveils Immune and Metabolism-Driven Subtypes with Implications for Anti-Nucleotide Metabolism Therapy

Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma

Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?

Study on Proteomic Profile of Normal Ependyma and Ependymoma of Spinal Cord by Using Three-Diamensional Shot-gun and MS/MS Technology